相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Pier Luigi Zinzani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Liang Zhang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Alan G. Ramsay et al.
BLOOD (2009)
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy
J. Griggs et al.
BRITISH JOURNAL OF CANCER (2009)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella et al.
BLOOD (2008)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
JW Friedberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)